Bilihome

Company profile

Bilihome is a Dutch medtech company redefining neonatal jaundice treatment for newborns through wearable phototherapy. Founded in 2019 and headquartered in Nijkerk, the company’s mission is to eliminate parent and child separation during treatment. Its clinically validated solution enables babies to stay in their parents’ arms while receiving hospital grade care. Having evolved from a research-driven venture into a commercial scaleup, Bilihome is preparing for market entry in 2025. The patented product line includes CE-certified garments and a wearable light therapy device currently under final review for CE approval. Bilihome offers hospitals a smart and cost effective alternative that shortens hospital stays, reduces nursing time, and frees up beds while improving outcomes for families.

The solution 

Bilihome Jauni® is a soft, wearable phototherapy romper that enables effective, hospital-grade treatment while supporting breastfeeding and bonding. The device is safe, CE-in-progress, and designed for both hospital and home settings. Recurring revenue is generated through the garments (Jauni Newborn Kit), which are single use and hold the Jauni system kit during treatment.

Traction and growth 

Pre-commercial traction is the entry point for the commercialization. We managed:

• Successful completion of pre-commercial studies for publication of superiority in natural care and usability.
• 150 leads, 18 Buy & Try intentions and 7 research requests is the result from European jENS conference.
• 85 leads come from the European Union and 11 from the United Kingdom
• In addition, there is a strong commercial interest from two hospital chains, one in the USA and one in Saudi Arabia.

The company will launch in The Netherlands in 2025, followed by Germany and the Nordics. Expansion to Asia and the Middle East is planned in the future through distributors and strategic partnerships.

Bilihome is targeting the €3 billion global jaundice treatment market with a scalable, low-CapEx model and growing international recognition.

Company info 

Products and services

Bilihome offers two integrated products that combine smart medical technology with family-centered care: the Jauni Wearable Phototherapy system, a lightweight, wearable device for treating neonatal jaundice while keeping babies close to their parents, and the Remote Care App, a digital tool that guides parents through home treatment while allowing healthcare staff to monitor progress remotely. Together, they deliver continuous, clinically validated therapy with lower costs for hospitals and a more comforting experience for families.

The Jauni Wearable Phototherapy system is Bilihome’s patented medical device designed to treat neonatal jaundice while keeping babies close to their parents. It replaces traditional incubator-based treatments with a lightweight, wearable solution that delivers continuous, clinically validated light therapy in both hospital and home settings.

The system is made up of three integrated components:

The Jauni system allows babies to receive continuous treatment even during breastfeeding or diaper changes, avoiding unnecessary interruptions. Its special light-shielding fabric eliminates the need for eye goggles, making the experience more comfortable for newborns. The device is lightweight, easy to handle, and comes with clear instructions, ensuring safe and intuitive use for both medical staff and parents. Thanks to the snug-fitting organic romper, babies can remain in close contact with their parents throughout the treatment, supporting bonding and emotional wellbeing. 

The Remote Care Service extends Bilihome’s solution into the home by connecting parents and healthcare providers through a digital interface. The companion Remote Care App gives parents clear, step-by-step instructions and lets them log key health indicators such as feeding frequency, diaper output, and general wellbeing.

Meanwhile, hospital staff can remotely monitor this data through a secure professional dashboard, ensuring that treatment remains safe, supported, and consistent with hospital standards.

Business model

Bilihome has developed a business model that combines medical impact with economic efficiency — generating revenue through a mix of device sales, recurring pay-per-use services, and long-term service agreements with hospitals. This model not only supports rapid market entry, but also provides a strong foundation for sustainable growth.

Direct sales in Europe 

In core European markets, Bilihome will market and distribute directly to hospitals. The rollout will begin in the Benelux in 2025, followed by Germany and the Nordics in 2026, and expansion to the UK and France in 2027. Italy and Spain will be covered through exclusive local distribution partners. 

Global distribution through strategic partners 

Outside of Europe, Bilihome will work with local distribution partners, starting in 2026. These include: 

• Saudi Arabia and the Emirates, where hospitals have directly invited Bilihome to pilot and launch the solution after local regulatory approval 

• The United States, following a completed trial with a major hospital group 

• India, China, and Indonesia, where Bilihome has gained early traction through clinical trials, visibility from winning the Design Intelligence Award, and strong regional interest 

The first revenues from Asia are expected in 2028, after the establishment of a regional supply chain. 

Clinical services and care path transition 

In all markets, Bilihome supports hospitals in transitioning care pathways from NICUs and incubators to maternity wards or home-based care, depending on national practices. This transformation improves hospital efficiency and patient-family experience. 

Revenue model 

Bilihome earns revenue through three core streams: 

• Device sales to hospitals 

• Recurring revenue from single-use newborn treatment kits, required for each jaundice case 

• Service fees for care pathway implementation and hospital onboarding 

Each treatment replaces the need for an incubator and provides hospitals with a flexible, scalable, and patient-friendly alternative to traditional phototherapy. 

Market

Jaundice is  the 7th most common medical condition in newborns. Around 60% of term babies and 80% of preterm babies will develop jaundice in the first week of life. Whereas most of the newborns recover without treatment, 10.5% of all newborns globally need to be treated with blue light phototherapy. This counts for 14 million newborns, which means every 2.3 seconds one newborn needs treatment.

Market Size and Growth

• Total Addressable Market: With a global healthcare expenditure of €3 billion in this space, there is strong potential to scale Bilihome internationally. Each year, 14 million newborns worldwide require phototherapy, highlighting a substantial and growing need for effective solutions.

• Serviceable Addressable Market (SAM): Estimated at €1.3 billion, based on 4.2 million newborns in Europe, North America, and Southeast Asia.

• Serviceable Obtainable Market (SOM): Estimated at €142 million, with a focus on reaching 275,000 newborns annually in the European Union alone.

Growth:

• The phototherapy market is expected to grow by approximately 6.5% per year, driven by rising birth rates, improved diagnostics, and increasing demand for treatments that allow parents and babies to stay together.
• Still, 50% — or 7 million newborns — are not adequately treated, presenting a growing opportunity for societal impact, particularly in Africa, Southeast Asia, China, and India.

Competitive Landscape

There is currently no scalable, wearable solution that enables effective jaundice treatment without separating newborns from their caregivers. Bilihome’s miniaturized, wearable phototherapy device offers a unique, patient-centric approach to natural care with zero separation.

Bilihome addresses this gap with a clinically validated, fully mobile solution suitable for both hospital and home use.

The company is well positioned to lead a shift away from intrusive clinical care, such as incubators or bulky fiber optic systems, toward family-integrated care. This approach aligns with global healthcare trends that prioritize early discharge and home-based treatment, while reducing the risk of hospital readmissions.

Bilihome’s solution is complemented by a Remote Care application that guides parents through each step of the treatment process.

Management

Distribution of company shares

Bilihome maintains a transparent and balanced shareholder structure that aligns long-term incentives and brings together deep sector expertise, operational commitment, and strategic growth support.

The founders collectively hold over 30% of the company, demonstrating strong personal commitment and long-term belief in Bilihome’s mission and success. CEO Margret Huenerbein and CCO Rick Wielens are both active shareholders through their respective companies, Anyango HealthDisrupt (16.70%) and LedSkin (12.76%), ensuring that leadership remains fully aligned with investor interests.

Beyond the founding team, Bilihome is supported by three strategic institutional shareholders:

• Oost NL with their two funds (MKB Kredietfaciliteit Gelderland B.V. 20.56 % and Innovatie-en Energiefonds Gelderland B.V. 5.47%): The regional development agency of East Netherlands brings not only growth capital, but also access to a strong regional and public innovation network. Oost NL actively supports Bilihome’s scaling efforts and its broader societal impact goals.

• Health Innovations (26.03%): As a healthcare-focused venture capital fund, Health Innovations contributes deep industry knowledge, access to medical networks, and strategic guidance tailored to medtech scale-ups. Their involvement strengthens Bilihome’s positioning in the clinical and reimbursement landscape.

• NLC Pooling BH B.V. (18.48%): As part of NLC, Europe’s leading healthtech venture builder, this shareholder represents the early innovation platform that helped build Bilihome. Their experience in validating clinical solutions and accelerating ventures from idea to market adds tremendous value to Bilihome’s operational and strategic execution.

Together, these shareholders form a well-rounded and synergistic ownership base, combining entrepreneurial drive, medtech expertise, institutional credibility, and long-term vision, all critical components to support Bilihome’s growth journey and international scaling strategy.

Company structure

Investors in this round will acquire shares in Bilihome B.V., the parent company registered in the Netherlands. There are no intermediate holding entities or subsidiaries involved.

Use of funds

Bilihome is on the verge of transitioning from a research-focused company to a commercial one. To support this transition, the company plans to raise €5 million. The majority of the funds will be allocated to sales efforts, leading to increased staffing and general administrative costs. Approximately 10% of the funding will be used for further research and development and product life cycle activities. The goal is to make the company profitable by 2027.

Even in the minimum funding scenario, this round is expected to bring Bilihome to break-even. No further investments are expected to be necessary if everything goes according to plan.

Of the total amount, €3.8 million is targeted from crowd investors. This will be complemented by €1.2 million in commitments from anchor investors.

The round is supported by Health Innovations, Oost NL, and the management team. Together, they have committed up to €1.2 million following thorough technical, commercial, and regulatory due diligence.

The funding will be used to expand the team, drive sales, support hospital implementation, and complete the necessary regulatory approvals.

Actual and planned figures

Get an insight into bilihome's financial figures, such as turnover and earnings development. Learn more about the growth forecast.

Bilihome enters this funding round with a pre-money valuation of €8 million, which is shared by both crowd investors and anchor investors, ensuring equal terms for all participants.

This round represents the first opportunity for external investors to participate at a stage where clinical validation is in place, market demand is proven, and commercial scale-up is about to begin.

Bilihome operates in a high-growth, innovation-driven sector where exit opportunities are common through acquisition, strategic investment, or secondary transactions. Below are three realistic pathways for investor returns: 

Alternative scenarios:

Investment related documents

Log in for more information.

Note:

In this update section you will find new, project-relevant information that we receive.

Invesdor does not conduct a separate review of information received after the start of the financing phase.

UPDATE on 12.06.2025: Why Invest in Jaundice Care for Zero Separation?

In this short video, CEO Margret Huenerbein explains why investing in Bilihome means contributing to better care, stronger families, and a more efficient healthcare system: 
 

Bilihome has recently achieved key milestones - ISO 13485 certification, two successful clinical trials, and recognition through three innovation awards. With over 150 hospitals already in the sales pipeline and a committed core team, the company is well-positioned to scale.

A €3.5 million investment will enable Bilihome to ramp up production and distribution, tapping into a €3 billion global market for neonatal jaundice treatment. The goal: to achieve up to five-fold valuation growth while delivering measurable impact and attractive return potential.

This is an opportunity to help redefine jaundice care - keeping newborns close to their families, reducing healthcare costs, and improving outcomes worldwide.